Weekly Market Report ยท Issue 3
Bond Yield Pressure Halts Three-Week Streak
U.S. equities ended a three-week winning streak as long-term Treasury yields climbed toward cycle highs, overwhelming a midweek expansion of Treasury buybacks. Energy remained the clear outlier as oil supply risk around the Strait of Hormuz kept crude elevated, while Technology and Consumer Discretionary absorbed the heaviest selling.
The issue at a glance
The Two-Minute Brief
As of August 21, 2026 ยท 4:00 PM ET
Confidence fell from 65% to 60% as the equity rally stalled under long-end yield pressure, geopolitical oil risk and unresolved trade uncertainty.
- Bond yields broke the equity streak. The S&P 500 fell about 1.4% for the week as long-dated Treasury yields returned toward cycle highs despite Treasury's expanded buyback program.
- Energy remained the leadership exception. WTI finished near $87 per barrel and rose more than 5% for a second straight week as disruptions around the Strait of Hormuz sustained a geopolitical supply premium.
- Growth and consumer cyclicals absorbed the damage. Technology and Consumer Discretionary lagged as higher discount rates pressured long-duration assets and major retail commentary reinforced a more selective consumer backdrop.
Persistent long-end yield pressure can tighten financial conditions and compress valuations even while the primary equity trend remains intact.
Seven technical reviews across nine charts, with Vince's commentary directly beneath each chart.
Interpretation, not information
Vince's View
U.S. equities shifted from Risk-On into a more disciplined digestion phase. The structural uptrend has not been invalidated, but the combination of higher real yields, heavy Treasury supply and geopolitical energy risk is forcing investors to demand a larger risk premium from long-duration assets.
Long-end Treasury yields resumed their climb, with the 10-year pushing toward 4.75% and the 30-year reaching its highest area since 2007 before Treasury's buyback announcement briefly eased pressure.
Investors are still willing to own risk, but not indiscriminately. Higher funding costs are being reflected in the valuation of growth equities while fiscal-supply concerns remain unresolved.
Energy remained the clearest leadership group as WTI closed near $87 and shipping through the Strait of Hormuz stayed well below normal levels.
Technology, semiconductors, Consumer Discretionary and rate-sensitive real estate remain exposed if long-end yields continue to rise.
Kevin Warsh's Jackson Hole keynote, Treasury-market demand, inflation and growth data, and whether market breadth can stabilize beyond Energy and defensive groups.
Trend, participation and cross-asset evidence
Market Regime Dashboard
Deteriorated. The S&P 500 ended the week at 7,674.37 after a roughly 1.4% weekly decline from recent record territory.
Small caps showed relative resilience late in the week even as technology weightings dragged the major averages lower.
Deteriorated from neutral as growth sectors broke short-term support and systematic selling increased.
Equity and fixed-income volatility expanded as long-bond yields surged, briefly reversed on Treasury action, then remained historically elevated.
The 30-year Treasury reached its highest yield since 2007 before the Treasury doubled planned long-bond buybacks to at least $4 billion per operation.
Capital rotated toward Energy, defensives, gold and other hard assets while investors reduced exposure to rate-sensitive growth.
Primary trends remain intact, but rates and supply dynamics justify tighter selectivity.
Confidence dropped five points as the prior three-week equity rally ended under fixed-income pressure.
Energy leadership
Crude supply constraints and geopolitical friction continue to produce a return stream that is diverging positively from the broader equity tape.
Long-end yields
Higher Treasury yields are compressing valuation tolerance across long-duration growth assets.
Supply and policy
Heavy fiscal issuance and uncertain Fed policy remain the key macro constraint on the risk-on thesis.
Direction matters more than a single return
Sector Analysis
VMF ranks Vince Vora's momentum assessment from 1 (strongest) to 12 (weakest). This week's proposed ranking blends current performance, change versus last week, relative strength and Vince's qualitative read. Click the VMF heading to sort.
| Sector / ETF | Current week | Prior week | Interpretation | |
|---|---|---|---|---|
| Energy (XLE) | +3.10% | +3.85% | Leading: crude oil extended gains as Hormuz disruptions kept supply risk elevated. | 1 |
| Health Care (XLV) | +0.45% | +0.30% | Leading defensively as investors favored steadier cash-flow exposure during rate volatility. | 2 |
| Materials (XLB) | +0.25% | +0.75% | Outperformed the broader market with support from industrial metals and chemical producers. | 3 |
| Industrials (XLI) | -0.35% | +0.45% | Aerospace and defense resilience was offset by softer transport and logistics exposure. | 4 |
| Financials (XLF) | -0.60% | +0.15% | Mixed as volatile long-end yields complicated the net-interest-margin outlook. | 5 |
| Communication Services (XLC) | -0.95% | +0.20% | Softened with mega-cap growth as broader technology risk appetite paused. | 6 |
| Consumer Staples (XLP) | -1.05% | +1.14% | Paused after prior-week gains as flows favored Energy and other defensive exposures. | 7 |
| Utilities (XLU) | -1.25% | -1.10% | Bond-proxy equities remained pressured by higher Treasury yields. | 8 |
| Real Estate (XLRE) | -1.40% | -0.85% | Rate-sensitive REITs weakened further under elevated financing costs. | 9 |
| Consumer Discretionary (XLY) | -1.85% | -2.10% | Weakening as retail commentary reinforced a selective consumer backdrop. | 10 |
| Technology (XLK) | -2.50% | +1.10% | Sharp deterioration as semiconductor profit-taking and higher discount rates hit growth leadership. | 11 |
| Retail (XRT) | -2.85% | -2.85% | Lagging for a second week as traffic and margin concerns remained unresolved. | 12 |
Energy stays at the front
Energy retained the top VMF rank as crude posted another strong week on geopolitical supply constraints.
Defensives gain relevance
Health Care and Materials provided relative stability while rates pressured long-duration assets.
Growth and Retail dragged
Technology suffered the sharpest momentum reversal while Retail remained at the bottom after a second consecutive weak week.
Follow the capital, not the headline
Inside the C-Suite
Selected Form 4 disclosures again showed far more insider selling than open-market buying during August 17โ21. The important distinction is motive: several of the largest sales were scheduled, option-related or tax-driven, while the week's most notable fresh-capital purchase came from Energy Transfer's Kelcy Warren.
| Company | Insider | Action | Approx. value | Context |
|---|---|---|---|---|
| Chime Financial (CHYM) | DST Global Advisors ยท 10% owner | Sale | $156.9M | Aug. 18โ19; roughly 4.81M shares disclosed. |
| Snowflake (SNOW) | Frank Slootman ยท Director | Sale | ~$97.4M | Recent filings indicate sales under a Rule 10b5-1 plan. |
| Astera Labs (ALAB) | Jitendra Mohan & Sanjay Gajendra | Sell-to-cover | ~$61.6M combined | Mandatory tax-withholding sales tied to vested RSUs. |
| Aura Minerals (AUGO) | Bruno Sousa Mauad ยท Director | Sale | $22.87M | 280,000 shares sold Aug. 19. |
| Adaptive Biotechnologies (ADPT) | Chad Robins ยท CEO / Chair | Option-related sale | $14.88M | Sales followed option exercises on Aug. 17โ18. |
| Micron (MU) | Sumit Sadana ยท EVP / CBO | Sale | $14.01M | 15,000 shares associated with an Aug. 18 filing. |
| PACS Group (PACS) | Jason Hulse Murray ยท CEO | 10b5-1 sale | $10.44M | 236,116 shares sold Aug. 17โ19 under a prearranged plan. |
| Energy Transfer (ET) | Kelcy Warren ยท Director / 10% owner | Purchase | $21.26M | 1.0M units bought Aug. 18โ19 around $21.26. |
| Zentalis Pharma (ZNTL) | Walters Group ยท 10% owner / Director | Purchase | $15.17M | 4.34M shares at $3.50; transaction dated Aug. 14 and disclosed during the week. |
Why the selling is not automatically bearish
Scheduled plans, option exercises and mandatory tax withholding can create large headline sales without conveying a discretionary view on valuation. Insider selling is usually less informative than genuine open-market buying because executives sell for many reasons but typically buy for one: expected value.
Vince's takeaway
The cleaner signal this week is the selective fresh-capital buying. Energy Transfer stands out because Kelcy Warren added roughly $21.3 million even with the units near multi-year highs.
Fixed income is driving the equity conversation
The Bond Corner
The bond market remained the principal source of cross-asset tension. Long-duration Treasury yields surged before a surprise Treasury intervention temporarily improved liquidity, but the underlying fiscal and inflation debate was not resolved.
Treasury announced that liquidity-support buybacks for 10- to 30-year securities will increase from $2 billion to at least $4 billion per operation beginning September 9. Secretary Scott Bessent subsequently said the size could rise further.
The 30-year yield reached roughly 5.34%, its highest level since 2007, before the buyback announcement triggered a sharp but incomplete reversal.
With Treasury policy now actively influencing the long end, Fed Chair Kevin Warsh's first Jackson Hole keynote takes on added significance for inflation expectations and the path of rates.
What matters next
- Inflation and growth: July Personal Income and Outlays, including PCE inflation, and the second estimate of Q2 GDP arrive Wednesday morning.
- Debt absorption: Watch whether private demand for Treasury issuance improves as the market digests the expanded buyback program.
- Central-bank guidance: Warsh speaks Friday at 10:00 AM ET from Jackson Hole. A clearer stance on inflation and rate policy could reset the entire yield curve.
Charts first, interpretation directly below
Technical Focus
Technical reviews supplied by Vince Vora. All charts are as of August 21, 2026 at 4:00 PM ET. Click any chart to expand it.
Bitcoin closed back above its rising 40-week moving average after defending the $65,000โ$70,000 demand zone. Medium-term momentum has improved, but price is pushing into an overhead resistance zone around $82,000โ$85,000. A decisive weekly close through that area would clear a meaningful supply band and strengthen the case for a retest of the prior highs.
The FTSE 100 is consolidating near multi-month highs while maintaining a sequence of higher lows above its rising 40-week moving average. Vince is focused on the resistance area near 10,990. A decisive weekly breakout and close above that level would confirm continuation; failure there would keep the index inside its current compression pattern.
Devon Energy pushed higher within a multi-year consolidation and reclaimed its rising 40-week moving average. Price is testing the upper boundary of a broad symmetrical triangle near $50. A weekly breakout above that descending resistance would materially improve the long-term structure; rejection would leave the stock range-bound.
On the weekly timeframe, Hecla defended structural support below $14 and closed back above its 40-week moving average. The rebound improves the medium-term structure and keeps the prior breakout zone intact. Vince will watch for sustained follow-through rather than a one-week reclaim.
The monthly chart shows the broader context: a long-term base has already broken higher, followed by a pullback into the prior breakout region. With the major demand zone still holding, the long-term structure remains constructive while price works through the volatility created by the earlier surge.
Maravai retested a prior resistance-turned-support area near $5 on exceptionally heavy volume while remaining above its 40-week moving average. The volume response is the key feature. Continued defense of that zone would support a continuation thesis; a sustained break back below it would undermine the setup.
Teva is pressing against a major resistance band near the mid-$30s after a multi-year advance above its rising 40-week moving average. The weekly chart is attempting a breakout through prior highs. Vince is watching for a clean close above the resistance zone rather than an intraday move alone.
The monthly chart reinforces the scale of Teva's recovery from its long-term $8โ$10 accumulation base. Price has returned to the major $35โ$37 resistance zone. A durable monthly breakout would mark an important structural transition; failure to hold above the zone would argue for more consolidation.
Featured research profile
GILD ยท Gilead Sciences
A cash-rich HIV franchise re-rating on long-acting prevention
Gilead's operating business is much stronger than the Q2 headline loss suggests. Revenue reached a record $7.8 billion and operating cash flow was $3.6 billion, while the reported loss was dominated by acquisition-related IPR&D and impairment charges. The central question is whether long-acting HIV prevention can extend the franchise runway enough to justify a valuation that is richer than Gilead's recent history.
Gilead shows a strong continuation structure after a major long-term base breakout. On the weekly chart, price pulled back into the prior breakout area and rising 40-week moving average around $115โ$120, held that support, formed a higher low and rotated higher. The immediate technical test is the first target area around $157.
The monthly chart reinforces the long-term strength. Price has expanded out of the multi-year $60โ$80 base and is advancing toward the first Fibonacci target around $157.31. Vince's higher reference levels are approximately $182.37 and $216.51, but the key near-term question is whether price can clear and hold above the first target zone.
The one thing to understand first
Gilead reported a Q2 2026 GAAP net loss of roughly $10.5 billion, or ($8.45) per share. That headline does not describe the underlying quarter. The result was dominated by $11.2 billion of acquired IPR&D expense tied primarily to the Arcellx, Tubulis and Ouro Medicines acquisitions, plus a $1.75 billion IPR&D impairment related to assets acquired from Immunomedics. These accounting charges obscure the operating performance, but the transactions themselves did consume real capital: Gilead reported $11.3 billion of acquisition-related cash outflows year to date.
Operationally, the quarter was strong: $7.8 billion of revenue, up 10% year over year, and $3.6 billion of operating cash flow. For this reason, product revenue, franchise growth and cash generation are more informative than the trailing P/E or GAAP net-income line this year.
Business quality & moat
HIV remains the core franchise. Q2 HIV sales rose 12% to $5.7 billion, led by Biktarvy at $3.8 billion (+7%) and Descovy at $967 million (+48%). Importantly, Gilead attributes HIV growth to higher average realized price and demand; Biktarvy also benefited from favorable inventory dynamics. Trodelvy grew 26% to $457 million, while liver-disease products and Livdelzi also contributed to the base-business growth.
The strategic durability argument rests on Gilead's dominant HIV position and its push into long-acting prevention and treatment. That provides a credible way to extend the franchise beyond the eventual maturity of today's oral regimens. The counterweight is concentration: HIV still represents the majority of product sales, so a competitive or patent-related disruption in that franchise matters more than any single oncology asset.
Financial statement forensics
The cash-flow statement is the cleaner lens this quarter. Gilead produced $3.6 billion of operating cash flow despite the large GAAP loss. Product gross margin was 79.3% GAAP and 86.9% non-GAAP, broadly stable year over year. Gilead's own non-GAAP EPS was also negative because the company does not add acquired IPR&D back to that measure; full-year non-GAAP loss-per-share guidance is ($0.65) to ($0.30), including an estimated $9.08 per-share impact from acquired IPR&D and related taxes.
The balance sheet deserves more attention after the acquisition spree. Cash, equivalents and marketable debt securities fell to $3.2 billion at June 30 from $10.6 billion at year-end 2025. That does not create an immediate solvency concern, but it reduces the liquidity cushion and raises the hurdle for additional large transactions.
| Q2 2026 metric | Result | Why it matters |
|---|---|---|
| Total revenue | $7.8B ยท +10% | Record quarter with broad base-business growth. |
| HIV sales | $5.7B ยท +12% | Core franchise remains the main earnings engine. |
| Biktarvy | $3.8B ยท +7% | Demand, realized price and inventory dynamics supported growth. |
| Descovy | $967M ยท +48% | Strong prevention-market momentum. |
| Trodelvy | $457M ยท +26% | Oncology growth helps diversification. |
| Operating cash flow | $3.6B | Demonstrates underlying cash generation despite the reported loss. |
| Cash / securities | $3.2B | Liquidity cushion fell sharply following acquisitions. |
Valuation and what the market is pricing
The trailing P/E is not useful because the acquisition charges pushed trailing GAAP earnings negative. A more reasonable framing is normalized forward earnings power and free cash flow. At roughly $146, the stock is no longer the chronically discounted Gilead of the prior decade; the market is assigning a higher multiple because it sees a credible long-acting HIV prevention runway. That makes this a quality-at-a-fair-price setup rather than an obvious deep-value trade.
Bull case
- Long-acting prevention expands the HIV market and extends the franchise into the 2030s.
- Strong cash generation continues to fund dividends, buybacks and pipeline investment.
- At least one acquired oncology, immunology or ADC asset becomes a meaningful second growth engine.
Bear case
- HIV concentration creates outsized sensitivity to competitive or patent-related setbacks.
- The acquisition record remains uneven, with further impairments or weak returns on deployed capital.
- The valuation re-rating gets ahead of the underlying growth and long-acting adoption fails to meet expectations.
What matters now
The technical and fundamental stories are aligned more cleanly than the headline earnings suggest. GILD has already broken a major long-term base, successfully retested support and is now approaching the first major upside target around $157. Fundamentally, the HIV franchise is still growing at a double-digit rate while the quarter's reported loss is dominated by acquisition accounting. The key confirmation would be a sustained move through the first target alongside continued HIV and prevention growth. The biggest fundamental risk is not the current P/E screen; it is whether Gilead earns an adequate return on the capital it is deploying outside the core franchise.
The events most likely to alter the thesis
Risk & Event Calendar
A fresh read on housing demand while mortgage rates remain elevated.
The week's most important macro cluster. Growth revisions and PCE inflation can directly change the market's rate path.
Capital-goods demand offers a useful read on industrial momentum and business investment.
NVIDIA remains a major test of AI spending durability and the valuation tolerance of the broader technology complex.
The 2026 symposium opens with the theme โFinancial Innovation: Implications for Payments and Policy.โ
The clearest near-term opportunity for the Fed to reshape expectations around inflation, rates and the interaction with Treasury-market stress.
Gold futures produced a decisive weekly reversal, bouncing off structural support to close back above the rising 40-week moving average. That move ends the multi-month pullback and restores a constructive long-term posture. The next test is whether momentum can extend toward prior cycle highs without quickly losing the reclaimed moving average.